Lantheus Holdings, Inc. SEC filings LNTH
Lantheus Holdings, Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Aug 5, 2016. Its latest annual report, Form ARS, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 2, 2026 | — |
| DEFA14A | Additional proxy material | Sep 21, 2026 | — |
| DEFA14A | Additional proxy material | Sep 17, 2026 | — |
| DEFM14A | Filing | Sep 8, 2026 | — |
| PREM14A | Filing | Aug 26, 2026 | Aug 26, 2026 |
| DEFA14A | Additional proxy material | Aug 13, 2026 | — |
| DEFA14A | Additional proxy material | Aug 4, 2026 | — |
| DEFA14A | Additional proxy material | Aug 4, 2026 | — |
| DEFA14A | Additional proxy material | Aug 3, 2026 | — |
| DEFA14A | Additional proxy material | Aug 3, 2026 | — |
| DEFA14A | Additional proxy material | Mar 20, 2026 | — |
| DEF 14A | Proxy statement | Mar 20, 2026 | Apr 30, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 10, 2026 | Apr 30, 2026 |
| DEFA14A | Additional proxy material | Mar 21, 2025 | — |
| DEF 14A | Proxy statement | Mar 21, 2025 | May 1, 2025 |
| DEFA14A | Additional proxy material | Mar 15, 2024 | — |
| DEF 14A | Proxy statement | Mar 15, 2024 | Apr 25, 2024 |
| DEFA14A | Additional proxy material | Mar 17, 2023 | — |
| DEF 14A | Proxy statement | Mar 17, 2023 | — |
| DEFA14A | Additional proxy material | Mar 18, 2022 | — |
| DEF 14A | Proxy statement | Mar 18, 2022 | Apr 28, 2022 |
| DEFA14A | Additional proxy material | Mar 18, 2021 | — |
| DEF 14A | Proxy statement | Mar 18, 2021 | Apr 28, 2021 |
| DEFA14A | Additional proxy material | Apr 6, 2020 | — |
| DEFA14A | Additional proxy material | Mar 12, 2020 | — |
| DEF 14A | Proxy statement | Mar 12, 2020 | Apr 23, 2020 |
| DEFA14A | Additional proxy material | Apr 5, 2019 | — |
| DEFA14A | Additional proxy material | Mar 15, 2019 | — |
| DEF 14A | Proxy statement | Mar 15, 2019 | Apr 24, 2019 |
| DEFA14A | Additional proxy material | Mar 16, 2018 | — |
| DEF 14A | Proxy statement | Mar 16, 2018 | Apr 26, 2018 |
| PRE 14A | Preliminary proxy statement | Mar 2, 2018 | Apr 26, 2018 |
| DEFA14A | Additional proxy material | Mar 17, 2017 | — |
| DEF 14A | Proxy statement | Mar 17, 2017 | Apr 27, 2017 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- LNTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedford, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1521036
- Former names
- Lantheus MI Holdings, Inc. (until May 23, 2014)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.